Dupilumab improves respiratory symptoms in patients with moderate-to-severe COPD with type 2 inflammation in phase 3 BOREAS trial

被引：0
|
作者：
Papi, Alberto [1 ]
Bhatt, Surya P. [2 ]
Rabe, Klaus F. [3 ,4 ]
Hanania, Nicola A. [5 ]
Vogelmeier, Claus F. [6 ]
Bafadhel, Mona [7 ]
Christenson, Stephanie A. [8 ]
Singh, Dave [9 ]
Laws, Elizabeth [10 ]
Maloney, Jennifer [11 ]
Lu, Xin [10 ]
Bauer, Deborah [10 ]
Bansal, Ashish [11 ]
Robinson, Lacey B. [12 ]
Abdulai, Raolat M. [12 ]
机构：
[1] Univ Ferrara, Ferrara, Italy
[2] Univ Alabama Birmingham, Birmingham, AL USA
[3] LungenClin Grosshansdorf, Grosshansdorf, Germany
[4] Christian Albrechts Univ Kiel, Airway Res Ctr North, German Ctr Lung Res, Grosshansdorf, Germany
[5] Baylor Coll Med, Houston, TX USA
[6] Philipps Univ Marburg, German Ctr Lung Res DZL, Marburg, Germany
[7] Kings Coll London, Kings Ctr Lung Hlth, London, England
[8] Univ Calif San Francisco, San Francisco, CA USA
[9] Univ Manchester, Manchester Univ NHS Fdn Trust, Manchester, England
[10] Sanofi, Bridgewater, NJ USA
[11] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[12] Sanofi, Cambridge, MA USA
来源：
EUROPEAN RESPIRATORY JOURNAL | 2024年 / 64卷
关键词：
D O I：
10.1183/13993003.congress-2024.PA4786
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma
    Jackson, Daniel J.
    Bacharier, Leonard B.
    Phipatanakul, Wanda
    Sher, Lawrence
    Domingo, Christian
    Papadopoulos, Nikolaos
    Modena, Brian
    Li, Ning
    Xia, Changming
    Kamal, Mohamed A.
    Dillon, Myles
    Wolfe, Kelley
    Gall, Rebecca
    Amin, Nikhil
    Mannent, Leda P.
    Laws, Elizabeth
    Rowe, Paul J.
    Jacob -Nara, Juby A.
    Deniz, Yamo
    Lederer, David J.
    Hardin, Megan
    Xu, Christine
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (01) : 44 - +
  • [32] UPADACITINIB VERSUS DUPILUMAB IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS OF THE HEADS UP PHASE 3 TRIAL
    Blauvelt, Andrew
    Teixeira, Henrique D.
    Simpson, Eric L.
    Costanzo, Antonio
    De Bruin-Weller, Marjolein
    Barbarot, Sebastien
    Prajapati, Vimal H.
    Lio, Peter
    Hu, Xiaofei
    Wu, Tianshuang
    Liu, John
    Ladizinski, Barry
    Chu, Alvina D.
    Eyerich, Kilian
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 62 - 62
  • [33] Dupilumab Reduces Sputum Eosinophils, Mucus Plugging and Improves Ventilation in Patients With Moderate-to-Severe Asthma
    Svenningsen, S.
    Kjarsgaard, M.
    Haider, E.
    Serajeddini, H.
    Garrido, C. Venegas
    Konyer, N.
    Radford, K.
    Huang, C.
    Lavigne, N.
    Friedlander, Y.
    Thakar, A.
    Radadia, N.
    Nasir, N.
    Mukherjee, M.
    Boylan, C.
    Kirby, M.
    Nair, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [34] DUPILUMAB IMPROVES ASTHMA CONTROL IN PATIENTS WITH UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA, REGARDLESS OF EXACERBATION HISTORY
    Corren, J.
    Castro, M.
    Maspero, J.
    Cosio, B.
    Kuna, P.
    Chen, Z.
    Staudinger, H.
    Chao, J.
    Nikhil, A.
    Ruddy, M.
    Akinlade, B.
    Graham, N.
    Teper, A.
    Khan, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S42 - S43
  • [35] Dupilumab efficacy in children with uncontrolled, moderate-to-severe type 2 asthma, with and without evidence of allergy, in the phase 3 VOYAGE study
    Papadopoulos, N. G.
    Szefler, S. J.
    Bacharier, L. B.
    Maspero, J. F.
    Domingo, C.
    Daizadeh, N.
    Lederer, D. J.
    Hardin, M.
    Jacob-Nara, J. A.
    Deniz, Y.
    Gall, R.
    Ortiz, B.
    Djandji, M.
    Rowe, P.
    ALLERGY, 2021, 76 : 175 - 176
  • [36] Dupilumab treatment induces clinical remission in patients with uncontrolled, moderate-to-severe, type 2 inflammatory asthma
    Pavord, I.
    Pandit-Abid, N.
    Israel, E.
    Szefler, S.
    Brusselle, G.
    Rabe, K.
    Chen, Z.
    Altincatal, A.
    Amin, N.
    Khan, A.
    Lederer, D. H.
    Zhang, Y.
    Rowe, P. J.
    Deniz, Y.
    Amr, R.
    Jacob-Nara, J. A.
    Busse, W. W.
    ALLERGY, 2023, 78 : 206 - 207
  • [37] Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids dose
    Pavord, Ian D.
    Bourdin, Arnaud
    Papi, Alberto
    Domingo, Christian
    Corren, Jonathan
    Altincatal, Arman
    Radwan, Amr
    Pandit-Abid, Nami
    Jacob-Nara, Juby A.
    Deniz, Yamo
    Rowe, Paul J.
    Laws, Elizabeth
    Lederer, David J.
    Hardin, Megan
    ALLERGY, 2023, 78 (11) : 2921 - 2932
  • [38] Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization
    Corren, Jonathan
    Jackson, David J.
    Casale, Thomas B.
    Borish, Larry
    Rabe, Klaus F.
    Busse, William W.
    Maspero, Jorge F.
    Jackson, Daniel J.
    Daizadeh, Nadia
    Altincatal, Arman
    Radwan, Amr
    Khodzhayev, Angela
    Djandji, Michel
    Jacob-Nara, Juby A.
    Rowe, Paul J.
    Deniz, Yamo
    JOURNAL OF ASTHMA AND ALLERGY, 2023, 16 : 249 - 260
  • [39] FUNCTIONAL RESPIRATORY IMAGING IN PATIENTS WITH MODERATE-TO-SEVERE ASTHMA: THE VESTIGE TRIAL
    Cox, J.
    Fogarty, C.
    Papi, A.
    Dimov, D.
    Ardeleanu, M.
    Mignot, B.
    De Backer, J.
    DePrado-Gomez, L.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (05) : S35 - S35
  • [40] COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab
    Ungar, Benjamin
    Glickman, Jacob W.
    Golant, Alexandra K.
    Dubin, Celina
    Marushchak, Olga
    Gontzes, Alyssa
    Mikhaylov, Daniela
    Singer, Giselle K.
    Baum, Danielle
    Wei, Nancy
    Sanin, Antonio
    Gruenstein, Diana
    Lebwohl, Mark G.
    Pavel, Ana B.
    Guttman-Yassky, Emma
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (01): : 134 - 142
12345